Canada Markets open in 3 hrs 22 mins

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
15.80-0.09 (-0.57%)
At close: 04:00PM EST
16.07 +0.27 (+1.71%)
After hours: 05:12PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close15.89
Bid0.00 x 28000
Ask15.79 x 4000
Day's Range15.69 - 15.83
52 Week Range12.28 - 16.30
Avg. Volume2,807,720
Market Cap49.22B
Beta (5Y Monthly)0.75
PE Ratio (TTM)30.04
EPS (TTM)0.53
Earnings DateN/A
Forward Dividend & Yield0.73 (5.60%)
Ex-Dividend DateMar 30, 2022
1y Target Est17.63
  • GlobeNewswire

    HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

    — HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Europe and Japan planned to complete in 2023 — — Partnership approach aligned with HUTCHMED’s path to profitability and strategy to bring its innovative medicines to patients worldwide — — HUTCHMED to host a conference call and webcast at 8:30 a.m. EST (1:30 p.

  • Business Wire

    Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

    OSAKA, Japan & CAMBRIDGE, Mass., January 23, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited (Nasdaq/AIM: HCM, HKEX: 13) and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau.

  • Reuters

    Slumping China-bound Japanese exports raise fears of global downturn

    Japan's export growth slowed sharply in December as China-bound shipments fell for the first time in seven months, stoking fears of further slowdown in the global economy and external demand for Japanese shipments. Exports rose 11.5% year-on-year in December after a gain of 20% in November, marking the slowest growth since the start of 2022, dragged down by a fall-off in sales to China of cars, auto parts and chip-making machinery, Ministry of Finance (MOF) data showed on Thursday. Exports to largest trading partner China fell 6.2% year-on-year in value and were down 24% in volume terms in December.